Creo Medical Group's revenue is forecast to decline at 4.9% per annum while its annual earnings are expected to grow at 41% per year. EPS is expected to grow by 45.6% per annum. Return on equity is forecast to be -14.7% in 3 years.
Key information
41.0%
Earnings growth rate
45.6%
EPS growth rate
Medical Equipment earnings growth
14.3%
Revenue growth rate
-4.9%
Future return on equity
-14.7%
Analyst coverage
Low
Last updated
24 Oct 2024
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
BST:1RC - Analysts future estimates and past financials data (GBP Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2026
28
-11
-14
-13
2
12/31/2025
32
-11
-16
-15
3
12/31/2024
34
-19
-2
-16
3
6/30/2024
30
-22
-22
-20
N/A
3/31/2024
31
-22
-22
-21
N/A
12/31/2023
31
-22
-23
-22
N/A
9/30/2023
30
-23
-24
-22
N/A
6/30/2023
29
-25
-25
-23
N/A
3/31/2023
28
-26
-27
-24
N/A
12/31/2022
27
-27
-28
-25
N/A
9/30/2022
27
-28
-33
-27
N/A
6/30/2022
26
-28
-38
-30
N/A
3/31/2022
26
-26
-35
-28
N/A
12/31/2021
25
-25
-32
-26
N/A
9/30/2021
24
-23
-26
-22
N/A
6/30/2021
22
-21
-19
-19
N/A
3/31/2021
16
-21
-18
-18
N/A
12/31/2020
9
-20
-17
-16
N/A
9/30/2020
5
-19
-17
-16
N/A
6/30/2020
0
-17
-17
-16
N/A
3/31/2020
0
-17
-15
-14
N/A
12/31/2019
0
-16
-13
-12
N/A
6/30/2019
0
-13
-14
-13
N/A
3/31/2019
0
-12
-12
-11
N/A
12/31/2018
N/A
-10
-10
-10
N/A
12/31/2017
0
-8
N/A
-9
N/A
9/30/2017
0
-8
N/A
-8
N/A
6/30/2017
N/A
-8
N/A
-7
N/A
6/30/2016
1
-5
N/A
-5
N/A
2/29/2016
1
-3
N/A
-3
N/A
2/28/2015
N/A
-2
N/A
-2
N/A
2/28/2014
1
-2
N/A
-1
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1RC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1RC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1RC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1RC's revenue is expected to decline over the next 3 years (-4.9% per year).
High Growth Revenue: 1RC's revenue is forecast to decline over the next 3 years (-4.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1RC is forecast to be unprofitable in 3 years.